



DHS SCIENCE AND TECHNOLOGY

Master Question List for COVID-19 (caused by SARS-CoV-2)

Weekly Report

31 March 2020

For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at HACTechnologyCenter@hq.dhs.gov.



**Homeland
Security**

Science and Technology

DHS Science and Technology Directorate | MOBILIZING INNOVATION FOR A SECURE WORLD

CLEARED FOR PUBLIC RELEASE

FOREWORD

The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions.

Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following “master question list” that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, “What is the infectious dose?” and “How long does the virus persist in the environment?” The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research.

The information contained in the following table has been assembled and evaluated by experts from publicly available sources to include reports and articles found in scientific and technical journals, selected sources on the internet, and various media reports. It is intended to serve as a “quick reference” tool and should not be regarded as comprehensive source of information, nor as necessarily representing the official policies, either expressed or implied, of the DHS or the U.S. Government. DHS does not endorse any products or commercial services mentioned in this document. All sources of the information provided are cited so that individual users of this document may independently evaluate the source of that information and its suitability for any particular use. This document is a “living document” that will be updated as needed when new information becomes available.

SARS-CoV-2 (COVID-19)	Infectious Dose – How much agent will make a healthy individual ill?	Transmissibility – How does it spread from one host to another? How easily is it spread?	Host Range – How many species does it infect? Can it transfer from species to species?
<p>What do we know?</p>	<p>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. SARS-CoV-2 is the cause of coronavirus disease 19 (COVID-19). <i>Work using SARS-CoV-2</i></p> <ul style="list-style-type: none"> A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 was sufficient to infect cynomolgus macaques via combination intranasal and intratracheal exposure (10⁶ TCID₅₀ total dose).¹³² Macaques did not exhibit clinical symptoms, but shed virus from the nose and throat.¹³² Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of approximately 700,000 PFU (10⁶ TCID₅₀).⁵⁹ Rhesus macaques infected with 2,600,000 TCID₅₀ of SARS-CoV-2 by the intranasal, intratracheal, oral, and ocular routes combined recapitulate moderate disease observed in the majority of human cases.¹¹² Initial experiments suggest that SARS-CoV-2 can infect genetically modified mice containing the human ACE2 cell entry receptor; infection via the intranasal route (dose: 10⁵ TCID₅₀, approximately 70,000 PFU) causes light infection, however no virus was isolated from infected animals, and PCR primers used do not align well with SARS-CoV-2, casting doubt on this study.¹⁵ <p><i>Related Coronaviruses</i></p> <ul style="list-style-type: none"> The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).⁵⁷⁻⁵⁸ Genetically modified mice exposed intranasally to doses of Middle East respiratory syndrome coronavirus (MERS) virus between 100 and 500,000 PFU show signs of infection. Infection with higher doses result in severe syndromes.^{7, 48, 93, 174} 	<p>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles.</p> <ul style="list-style-type: none"> Pandemic COVID-19 has caused 838,061 infections and 41,261 deaths⁸⁰ in at least 180 countries and territories (as of 3/31/2020).^{32, 137, 161} In the US there are 177,452 confirmed SARS-CoV-2 cases across all 50 US states, with 3,440 deaths. (as of 3/31/2020)⁸⁰; sustained community transmission of COVID-19 is occurring in the US.¹⁸ High-quality estimates of human transmissibility (R₀) range from 2.2 to 3.1.^{108, 118, 129, 167, 173} SARS-CoV-2 is believed to spread through close contact and droplet transmission,³⁵ with fomite transmission likely⁸¹ and close-contact aerosol transmission plausible^{24, 71} but unconfirmed.¹⁶⁰ SARS-CoV-2 replicates in the upper respiratory tract (e.g., throat), and infectious virus is detectable in throat and lung tissue for at least 8 days.¹⁶³ Aerosolized virus has been detected in COVID-19 patient rooms, with particle sizes within the human respirable range (0.25 – 2.5 μm).¹⁰³ SARS-CoV-2 is present in infected patient saliva,¹⁴⁹ lower respiratory sputum,¹⁵⁵ and feces.⁹⁷ <p>Individuals can transmit SARS-CoV-2 to others before they have symptoms.</p> <ul style="list-style-type: none"> Pre-symptomatic¹⁷⁶ or asymptomatic¹³ patients can transmit SARS-CoV-2; between 12%⁶² and 23%¹⁰² of infections may be caused by asymptomatic or pre-symptomatic transmission. Severe cases are more likely to transmit disease; most new infections are within households of infected patients.¹⁰⁶ <p>Undetected cases play a major role in transmission.</p> <ul style="list-style-type: none"> Models suggest up to 86% of early COVID-19 cases in China were undetected, and these infections were the source for 79% of reported cases.⁹⁵ <p>Behavior changes may limit spread.⁶⁹</p> <ul style="list-style-type: none"> Social distancing and other policies are estimated to have reduced COVID-19 spread by 44% in Hong Kong⁵⁴ and reduced spread in China.⁸⁴ Modeling suggests that premature lifting of social distancing measures will substantially increase the number of local COVID-19 cases.¹¹⁹ 	<p>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans; the identity of the SARS-CoV-2 intermediate host is unknown.</p> <ul style="list-style-type: none"> Early genomic analysis indicates similarity to SARS-CoV-1,¹⁷⁹ with a suggested bat origin.^{5, 49, 179} Positive samples from the South China Seafood Market strongly suggests a wildlife source,³⁷ though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.^{19, 50, 168, 172} Analysis of SARS-CoV-2 genomes suggests that a non-bat intermediate species is responsible for the beginning of the outbreak.¹³¹ The identity of the intermediate host remains unknown.^{96, 99-100} Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago.⁸⁸ <p>SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.</p> <ul style="list-style-type: none"> Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1,¹⁶⁶ potentially explaining its high transmissibility; the same work suggests that differences between SARS-CoV-2 and SARS-CoV-1 Spike proteins may limit the therapeutic ability of SARS antibody treatments.¹⁶⁶ Modeling of SARS-CoV-2 Spike and ACE2 proteins suggests that SARS-CoV-2 can bind and infect human, bat, civet, monkey and swine cells.¹⁵³ There is currently no evidence that SARS-CoV-2 infects domestic animals or livestock.⁷⁸

SARS-CoV-2 (COVID-19)	Infectious Dose – How much agent will make a healthy individual ill?	Transmissibility – How does it spread from one host to another? How easily is it spread?	Host Range – How many species does it infect? Can it transfer from species to species?
<p>What do we need to know?</p>	<p>Identifying the infectious dose for humans by any exposure route will facilitate model development; animal studies are a plausible surrogate.</p> <ul style="list-style-type: none"> • Human infectious dose by aerosol route • Human infectious dose by surface contact (fomite) • Human infectious dose by fecal-oral route 	<p>Identifying the contribution of asymptomatic or pre-symptomatic transmission is important for implementing control measures. Additionally, the relative contribution of different infection sources – fomites, droplets, aerosols, and potentially feces – are unknown.</p> <ul style="list-style-type: none"> • Capability of SARS-CoV-2 to be transmitted by contact with fomites (phones, doorknobs, surfaces, clothing, etc.) – see also Experimental Stability • Superspreading capacity needs to be refined • Updated person to person transmission rates (e.g., R_0) as control measures take effect • What is the underreporting rate?⁷⁹ • Can individuals become re-infected with SARS-CoV-2? • What is the difference in transmissibility among countries? • Is the R_0 estimate higher in healthcare or long-term care facilities? • How effective are social distancing measures? • When will infections peak in various cities and countries? 	<p>Little is known about SARS-CoV-2 in non-human hosts.</p> <ul style="list-style-type: none"> • What is the intermediate host(s)? • What are the mutations in SARS-CoV-2 that allowed human infection and transmission? • What animals can SARS-CoV-2 infect (e.g., pet dogs, potential wildlife reservoirs)?

SARS-CoV-2 (COVID-19)	Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?	Clinical Presentation – What are the signs and symptoms of an infected person?	Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?
<p>What do we know?</p>	<p>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Some individuals never develop symptoms but can still transmit disease.</p> <ul style="list-style-type: none"> The best current estimate of the COVID-19 incubation period is 5.1 days, with 99% of individuals exhibiting symptoms within 14 days of exposure.⁹¹ Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.⁹¹ Individuals can test positive for COVID-19 even if they lack clinical symptoms.^{13, 39, 72, 145, 176} Individuals can be infectious while asymptomatic^{35, 133, 145, 176,} and asymptomatic individuals can have similar amounts of virus in their nose and throat as symptomatic individuals.¹⁸⁰ Infectious period is unknown, but possibly up to 10-14 days.^{5, 95, 137} On average, there are approximately 4⁶² to 7.5⁹⁴ days between symptom onset in successive cases of a single transmission chain. Most hospitalized individuals are admitted within 8-14 days of symptom onset.¹⁷⁸ Patients can test positive via PCR for up to 37 days after symptoms appear.¹⁷⁸ Patients can test positive after recovery and hospital discharge.⁸⁹ The ability of these individuals to infect others is unknown. <p>Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2.</p> <ul style="list-style-type: none"> Experimentally infected macaques were not capable of being reinfected after their primary infection resolved.¹⁴ According to the WHO, there is no evidence of re-infection with SARS-CoV-2 after recovery.⁹⁰ 	<p>Most COVID-19 cases are mild, but severe disease can be found in any age group. Older individuals and those with underlying medical conditions are at higher risk of serious illness and death.</p> <ul style="list-style-type: none"> The majority of COVID-19 cases are mild (81%, N = 44,000 cases)¹⁴⁵ Initial COVID-19 symptoms include fever (87.9% overall, but only 44% - 52% present with fever initially^{12, 72}), cough (67.7%⁷²), fatigue, shortness of breath, headache, and reduced lymphocyte count.^{36, 42, 76} Headache⁴¹ and diarrhea are uncommon,^{76, 94} though lack of appetite may be an early symptom.¹¹⁷ Complications include acute respiratory distress (ARDS, 17-29% of hospitalized patients,^{45, 76} leading to death in 4-15% of cases^{45, 76, 154}), pneumonia,¹¹⁶ cardiac injury (20%¹⁴¹), secondary infection, kidney failure, arrhythmia, sepsis, and shock.^{72, 76, 154, 178} Most deaths are caused by respiratory failure or respiratory failure combined with myocardial (heart) damage.¹³⁴ Approximately 15% of hospitalized patients are classified as severe,^{72, 145} and approximately 5% of patients are admitted to the ICU.^{72, 145} Current modeling suggests the overall case fatality rate (CFR) of COVID-19 is approximately 2.4%.¹¹ The CFR depends on comorbidities; cardiovascular disease, hypertension, diabetes, and respiratory conditions all increase the CFR.^{145, 178} The CFR increases with age; individuals >60 are at higher risk of death,^{145, 178} and >60% of confirmed fatalities have been male.¹⁴⁵ In the US, 34% of hospitalizations have been individuals younger than 44 years old.⁴ Variation in the CFR between countries may be due to demographics, testing criteria, and how COVID-19 related deaths are defined.¹¹⁴ Children of all ages are susceptible to COVID-19,⁶¹ though generally show milder^{43, 105} or no symptoms; up to 28% of children may be asymptomatic.¹²¹ Severe symptoms in children are possible,¹⁰¹ and infant deaths have been recorded.^{26, 105} Based on one patient, a productive immune response is generated and sustained for at least 7 days.¹⁴⁶ 	<p>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples. These tests are relatively accurate. Confirmed cases are still underreported.</p> <ul style="list-style-type: none"> US CDC has expanded patient testing criteria to include symptomatic patients at clinician discretion.¹⁷ PCR protocols and primers have been widely shared internationally.^{31, 52, 94, 140, 157, 162} PCR-based diagnostic assays are unable to differentiate between active and inactive virus. A combination of pharyngeal (throat) RT-PCR and chest tomography are the most effective diagnostic criteria (correctly diagnose 91.9% of infections).¹²⁶ A single throat swab detects 78.2% of infections; duplicate tests identify 86.2% of infections.¹²⁶ Nasal and pharyngeal swabs may be less effective as diagnostic specimens than sputum and bronchoalveolar lavage fluid.¹⁵⁵ RT-PCR tests can identify asymptomatic cases; SARS-CoV-2 infection was identified in 2/114 individuals cleared by clinical assessment.⁷⁵ Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.¹⁷⁵ The FDA released an Emergency Use Authorization enabling laboratories to develop and use tests in-house for patient diagnosis.⁶⁸ Updated tests from the US CDC are available to states.^{31, 35} Multiple rapid or real-time test kits have been produced by universities and industry, including the Wuhan Institute of Virology,⁵⁵ BGI,²¹ Cepheid¹⁵², Abbot,⁶⁶ and Mesa Biotech.²² The US CDC is developing serological tests to determine what proportion of the population has been exposed to SARS-CoV-2.⁸³ Machine learning tools are being developed to predict severe and fatal COVID-19 cases based on CT scans.¹⁴²

SARS-CoV-2 (COVID-19)	Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?	Clinical Presentation – What are the signs and symptoms of an infected person?	Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?
<p>What do we need to know?</p>	<p>While the incubation period is well-characterized, less is known about how long individuals are infectious before, during, and after symptoms. Additionally, the possibility of reinfection warrants more research.</p> <ul style="list-style-type: none"> • What is the average infectious period during which individuals can transmit the disease? • Are individuals infectious after hospital discharge and clinical recovery, or are positive PCR tests only detecting non-infectious virus? • Can individuals become re-infected after recovery? If so, how long after? 	<p>The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location</p> <ul style="list-style-type: none"> • How long does it take for infected individuals to recover outside of a healthcare setting? • Are reductions in CFR through time (e.g., China) an indication of better treatment, less overcrowding, or both? • Are pregnant women at greater risk of complications during labor?⁹⁸ • How prevalent is loss of smell, loss of taste and gastrointestinal symptoms in COVID-19 patients? 	<p>In general, PCR tests appear to be sensitive and specific, though robust estimates of false positive/negative rates are still lacking.</p> <ul style="list-style-type: none"> • False positive/negative rates for tests • Eclipse phase of infection (time between infection and detectable disease) in an individual • With limited testing in many locations, how accurate are clinical diagnoses compared to genetic tests?



SARS-CoV-2 (COVID-19)	Medical Treatment – Are there effective treatments? Vaccines?	Environmental Stability – How long does the agent live in the environment?	Decontamination – What are effective methods to kill the agent in the environment?
<p>What do we know?</p>	<p>Treatment for COVID-19 is primarily supportive care including ventilation if necessary.^{72, 109} A number of therapeutic trials are ongoing, but results are preliminary.²⁰ Convalescent sera is being tested at multiple sites across the US.¹¹⁰</p> <ul style="list-style-type: none"> • Two WHO global clinical trials are starting: Solidarity and Discovery.⁸⁶ These trials include remdesivir, hydroxychloroquine and chloroquine, ritonavir/lopinavir, and ritonavir/lopinavir and interferon-beta.⁸⁶ • Limited, preliminary evidence from clinical trials supports the efficacy of favipiravir,⁴⁴ tocilizumab,¹⁶⁹ intravenous immunoglobulin,²⁸ and hydroxychloroquine with azithromycin.⁷⁰ <i>Additional work is necessary to confirm therapeutic efficacy of any of these compounds.</i> • Limited, preliminary evidence shows mixed efficacy of chloroquine alone,¹ and no efficacy from combination ritonavir and lopinavir.²⁷ <i>Additional work is necessary to confirm the lack of efficacy of any of these treatments.</i> • Teams across the USA are testing passive antibody therapy (convalescent serum²⁹) to patients (FDA Investigational New Drug approval).⁶⁷ In a small trial (5 patients), convalescent sera administration was followed by clinical improvement.¹³⁹ • Corticosteroids are commonly given to COVID-19 patients¹⁷⁸ at risk of ARDS,¹⁷⁰ but their use is not recommended by the US CDC.³³ • Laboratory testing identified 17 repurposed drugs with significant antiviral activity; more research is needed to confirm efficacy.¹⁵⁶ <p>Work is ongoing to develop a SARS-CoV-2 vaccine in human and animal trials. No preliminary results are available.</p> <ul style="list-style-type: none"> • Multiple entities are working to produce a SARS-CoV-2 vaccine,⁸ including HHS/NIH/NIAID,^{73, 92} Moderna Therapeutics and Gilead Sciences,^{2-3, 113} Sanofi,²³ and Johnson and Johnson.⁸² Moderna has begun phase 1 clinical vaccine trials in humans in WA state.¹³⁰ • CEPI has partnered with multiple entities to develop vaccines including University of Oxford, Novavax Hong Kong University, and the Institut Pasteur. 	<p>SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown.</p> <p><i>SARS-CoV-2 Data</i></p> <ul style="list-style-type: none"> • SARS-CoV-2 can persist on plastic and metal surfaces between 3 days (21-23°C, 40% RH)¹⁵⁰ and 7 days (22°C, 65%RH). <i>Infectious virus can be recovered from a surgical mask after 7 days (22°C, 65% RH).</i>⁴⁶ • SARS-CoV-2 has an aerosol half-life of 2.7 hours (particles <5 µm, tested at 21-23°C and 65% RH).¹⁵⁰ • SARS-CoV-2 is susceptible to heat treatment (70°C), but can persist for at least two weeks at refrigerated temperatures (4°C).⁴⁶ • SARS-CoV-2 genetic material (RNA) was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days after cabins were vacated; the infectiousness of this material is not known.¹¹¹ <p><i>Surrogate Coronavirus data:</i></p> <ul style="list-style-type: none"> • Studies suggest that other coronaviruses can survive on non-porous surfaces up to 9-10 days (MHV, SARS-CoV)^{30, 40}, and porous surfaces for up to 3-5 days (SARS-CoV)⁶⁴ in air conditioned environments (20-25°C, 40-50% RH). • Coronavirus survival tends to be higher at lower temperatures and lower relative humidity (RH),^{30, 40, 123, 151} though infectious virus can persist on surfaces for several days in typical office or hospital conditions¹⁵¹. • SARS can persist with trace infectivity for up to 28 days at refrigerated temperatures (4°C) on surfaces.³⁰ • No strong evidence exists showing reduction in transmission with seasonal increase in temperature and humidity.¹⁰⁷ • One hour after aerosolization approximately 63% of airborne MERS virus remained viable in a simulated office environment (25°C, 75% RH)¹²⁰ • Porous hospital materials, including paper and cotton cloth, maintain infectious SARS-CoV for a shorter time than non-porous material.⁸⁷ 	<p>Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.</p> <p><i>SARS-CoV-2</i></p> <ul style="list-style-type: none"> • Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.⁸⁵ • Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.⁴⁶ • Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.¹¹⁵ • EPA has released a list of SARS-CoV-2 disinfectants, but solutions were not tested on live virus.⁶ <p><i>Other Coronaviruses</i></p> <ul style="list-style-type: none"> • Chlorine-based¹⁵⁹ and ethanol-based⁵¹ solutions are recommended. • Heat treatment (56°C) is sufficient to kill coronaviruses,^{123, 177} though effectiveness depends partly on protein in the sample.¹²³ • 70% ethanol, 50% isopropanol, sodium hypochlorite [0.02% bleach], and UV radiation can inactivate several coronaviruses (MHV and CCV).¹³⁵ • Ethanol-based biocides effectively disinfectant coronaviruses dried on surfaces, including ethanol containing gels similar to hand sanitizer.^{77, 164} • Surface spray disinfectants such as Mikrobac, Dismozon, and Korsolex are effective at reducing infectivity of the closely related SARS-CoV after 30 minutes of contact.¹²² • Coronaviruses may be resistant to thermal inactivation for up to 7 days when stabilized in stool.¹⁴⁷⁻¹⁴⁸ • Coronaviruses are more stable in matrixes such as respiratory sputum.⁶³ • Hydrogen peroxide vapor can repeatedly decontaminate N95 respirators.¹²⁸ Devices capable of decontaminating 80,000 masks per day have been granted emergency use authorization from the FDA.⁶⁵

SARS-CoV-2 (COVID-19)	Medical Treatment – Are there effective treatments? Vaccines?	Environmental Stability – How long does the agent live in the environment?	Decontamination – What are effective methods to kill the agent in the environment?
<p>What do we need to know?</p>	<p>In general, the efficacy of various therapeutic options for COVID-19 is unknown, though clinical trial results are beginning to be released.</p> <ul style="list-style-type: none"> • Is GS-5734 (remdesivir) effective in vivo (already used in clinical trials under Emergency Use Authorization)?¹³⁸ • Is the GLS-5000 MERS vaccine¹⁷¹ cross-reactive against SARS-CoV-2? • Efficacy of antibody treatments developed for SARS^{53, 144} and MERS³⁸ • What is the efficacy of various MERS and SARS Phase I/II vaccines and other therapeutics? • Are viral replicase inhibitors such as beta-D-N4-hydroxycytidine effective against SARS-CoV-2?²¹⁶ 	<p>Additional testing on SARS-CoV-2, not surrogate viruses, is needed to support initial estimates of stability.</p> <ul style="list-style-type: none"> • Stability of SARS-CoV-2 in aerosol, droplets, and other matrices (mucus/sputum, feces) • Particle size distribution (e.g., droplet, large droplet and true aerosol distribution) • Duration of SARS-CoV-2 infectivity via fomites and surface (contact hazard)? • Stability of SARS-CoV-2 on PPE (e.g., Tyvek, nitrile, etc.) 	<p>Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.</p> <ul style="list-style-type: none"> • What is the minimal contact time for disinfectants? • Does contamination with human fluids/waste alter disinfectant efficacy profiles? • How effective is air filtration at reducing transmission in healthcare, airplanes and public spaces? • Are landfills and wastewater treatment plants effective at inactivating SARS-CoV-2? • Is heat or UV decontamination effective to clean N95 respirators and other types of PPE for multi-use?



SARS-CoV-2 (COVID-19)	PPE – What PPE is effective, and who should be using it?	Forensics – Natural vs intentional use? Tests to be used for attribution.	Genomics – How does the disease agent compare to previous strains?
<p>What do we know?</p>	<p>The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.</p> <ul style="list-style-type: none"> Healthcare worker illnesses (over 1,000¹⁴⁵) demonstrates human-to-human transmission despite isolation, PPE, and infection control.¹³⁶ Risk of transmission to healthcare workers appears high, with up to 20% of healthcare workers in Lombardy, Italy becoming infected.¹²⁵ “Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield)”³⁴ WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.¹⁵⁸ Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those dealing with possible aerosols¹⁵⁹; additional protection, such as a Powered Air Purifying Respirator (PAPR) with a full hood, should be considered for high-risk procedures (i.e., intubation, ventilation).²⁵ Particular attention should be paid to the potential for transmission via exhaled air during supportive respiratory procedures.⁷¹ There is evidence both for¹⁰³ and against¹¹⁵ the detection of SARS-CoV-2 RNA via air sampling in patient rooms and other hospital areas. The efficacy of “homemade” PPE, made with T-shirts, bandanas, similar materials, is less than standard PPE, but may be used if no other options are available.^{47, 56, 127} 	<p>All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.</p> <ul style="list-style-type: none"> Genomic analysis places SARS-CoV-2 into the beta-coronavirus clade, with close relationship to bat coronaviruses. The SARS-CoV-2 virus is distinct from SARS-CoV-1 and MERS viruses.⁶⁰ Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by “recombination” with other circulating strains of coronavirus.^{9, 179} Genomic data support at least two plausible origins of SARS-CoV-2: “(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.”⁹ Either scenario is consistent with the observed genetic changes found in all known SARS-CoV-2 isolates. Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses¹⁶⁵; data suggests that pangolins may be a natural host for beta-coronaviruses⁹⁹⁻¹⁰⁰. Additional research is needed. Additionally, “[...] SARS-CoV-2 is not derived from any previously used virus backbone,” reducing the likelihood of laboratory origination,⁹ and “[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.”⁹ 	<p>Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity.</p> <ul style="list-style-type: none"> There have been no documented cases of SARS-CoV-2 prior to December 2019 Preliminary genomic analyses, however, suggest that the first human cases of SARS-CoV-2 emerged between 10/19/2019 – 12/17/2019.^{10, 19, 124} The mutation rate of SARS-CoV-2 is estimated to be similar to other RNA viruses (e.g., SARS, Ebola, Zika), and is currently calculated to be 1.04x10⁻³ substitutions per site per year (N = 116 genomes).⁷⁴ Pangolin coronaviruses are closely related to both SARS-CoV-2 and closely related Bat coronaviruses; phylogenetic analysis suggests that SARS-CoV-2 is of bat origin, but is closely related to pangolin coronavirus.⁹⁹⁻¹⁰⁰ The Spike protein of SARS-CoV-2, which mediates entry into host cells and is the major determinant of host range, is very similar to the Spike protein of SARS-CoV-1.¹⁰⁴ The rest of the genome is more closely related to two separate bat¹⁰⁴ and pangolin¹⁰⁰ coronavirus. Analysis of SARS-CoV-2 sequences from Singapore has identified a large nucleotide (382 bp) deletion in ORF-8.¹⁴³ The effect of this deletion on transmission or virulence is unknown.

SARS-CoV-2 (COVID-19)	PPE – What PPE is effective, and who should be using it?	Forensics – Natural vs intentional use? Tests to be used for attribution.	Genomics – How does the disease agent compare to previous strains?
<p>What do we need to know?</p>	<p>Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare worker is critical due to their high rates of infection.</p> <ul style="list-style-type: none"> • What is the importance of aerosol transmission? • What is the effective distance of spread via droplet or aerosol? • How effective are barriers such as N95 respirators or surgical masks? • What is the appropriate PPE for first responders? Airport screeners? • What are proper procedures for reducing spread in medical facilities / transmission rate in medical settings? • How effective are homemade masks at reducing transmission? 	<p>Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source.</p> <ul style="list-style-type: none"> • What tests for attribution exist for coronavirus emergence? • What is the identity of the intermediate species? • Are there closely related circulating coronaviruses in bats or other animals with the novel PRRA cleavage site found in SARS-CoV-2? 	<p>Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.</p> <ul style="list-style-type: none"> • Are there similar genomic differences in the progression of coronavirus strains from bat to intermediate species to human? • Are there different strains or clades of circulating virus? If so, do they differ in virulence?




Table 1. Definitions of commonly-used acronyms

Acronym/Term	Definition	Description
Attack rate	Proportion of “at-risk” individuals who develop infection	Defined in terms of “at-risk” population such as schools or households, defines the proportion of individuals in those populations who become infected after contact with an infectious individual
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Official name for the virus previously known as 2019-nCoV.
COVID-19	Coronavirus disease 19	Official name for the disease caused by the SARS-CoV-2 virus.
CFR	Case Fatality Rate	Number of deaths divided by confirmed patients
PFU	Plaque forming unit	Measurement of the number of infectious virus particles as determined by plaque forming assay. A measurement of sample infectivity.
TCID ₅₀	50% Tissue Culture Infectious Dose	The number of infectious units which will infect 50% of tissue culture monolayers. A measurement of sample infectivity.
HCW	Healthcare worker	Doctors, nurses, technicians dealing with patients or samples
SARS	Severe Acute Respiratory Syndrome	Coronavirus with over 8,000 cases in global 2002-2003 outbreak
MERS	Middle-East Respiratory Syndrome	Coronavirus with over 2,000 cases in regional outbreak since 2012
CoV	Coronavirus	Virus typified by crown-like structures when viewed under electron microscope
R ₀	Basic reproduction number	A measure of transmissibility. Specifically, the average number of new infections caused by a typical infectious individual in a wholly susceptible population.
MHV	Mouse hepatitis virus	Coronavirus surrogate

CCV	Canine coronavirus	Canine coronavirus
Fomite	Inanimate vector of disease	Surfaces such as hospital beds, doorknobs, healthcare worker gowns, faucets, etc.
Droplet transmission	Sneezing, coughing	Transmission via droplets requires relatively close contact (e.g., within 6 feet)
Airborne transmission	Aerosolization of infectious particles	Aerosolized particles can spread for long distances (e.g., between hospital rooms via HVAC systems)
Transgenic	Genetically modified	In this case, animal models modified to be more susceptible to MERS and/or SARS by adding proteins or receptors necessary for infection
Intranasal	Agent deposited into external nares of subject	Simulates inhalation exposure by depositing liquid solution of pathogen/virus into the nose of a test animal, where it is then taken up by the respiratory system.
Incubation period	Time between infection and symptom onset	Time between infection and onset of symptoms typically establishes guidelines for isolating patients before transmission is possible
Infectious period	Length of time an individual can transmit infection to others	Reducing the infectious period is a key method of reducing overall transmission; hospitalization, isolation, and quarantine are all effective methods
Serial interval	Length of time between symptom onset of successive cases in a transmission chain	The serial interval can be used to estimate R_0 , and is useful for estimating the rate of outbreak spread
Superspreading	One individual responsible for an abnormally large number of secondary infections	Superspreading can be caused by high variance in the distribution of secondary cases caused by a single individual; most individuals infect very few people, while some infect a large number, even with the same average number of secondary infections
Nosocomial	Healthcare- or hospital-associated infections	Characteristic of SARS and MERS outbreaks, lead to refinement of infection control procedures

ACE2	Angiotensin-converting enzyme 2	Acts as a receptor for SARS-CoV, allowing entry into human cells
ARDS	Acute respiratory distress syndrome	Leakage of fluid into the lungs which inhibits respiration and leads to death
PPE	Personal protective equipment	Gowns, masks, gloves, and any other measures used to prevent spread between individuals
PCR	Polymerase chain reaction	PCR (or real-time [RT] or quantitative [Q] PCR) is a method of increasing the amount of genetic material in a sample, which is then used for diagnostic testing to confirm the presence of SARS-CoV-2



Literature Cited:

1. (U) French researcher posts successful Covid-19 drug trial. *Connexion*: 2020. <https://www.connexionfrance.com/French-news/French-researcher-in-Marseille-posts-successful-Covid-19-coronavirus-drug-trial-results>
2. (U) A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults 2020. <https://clinicaltrials.gov/ct2/show/NCT04280705>
3. (U) Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults 2020. <https://clinicaltrials.gov/ct2/show/record/NCT04283461?term=mrna-1273&draw=2&rank=1>
4. (U) Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. *MMWR* **2020**. https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s_cid=mm6912e2_w#suggestedcitation
5. (U) [Wuhan Pneumonia] The Hospital Authority stated that 2 critically ill patients needed external life support treatment. <https://www.singtao.ca/4037242/2020-01-14/news-%E3%80%90%E6%AD%A6%E6%BC%A2%E8%82%BA%E7%82%8E%E3%80%91%E9%86%AB%E7%AE%A1%E5%B1%80%E6%8C%87%E5%90%8D%E9%87%8D%E7%97%87%E7%97%85%E6%82%A3%E9%9C%80%E9%AB%94%E5%A4%96%E7%94%9F%E5%91%BD%E6%94%AF%E6%8C%81%E6%B2%BB%E7%99%82/?variant=zh-hk>
6. (U) Agency, U. S. E. P., EPA's Registered Antimicrobial Products for Use Against Novel Coronavirus SARS-CoV-2, the Cause of COVID-19. <https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>.
7. (U) Agrawal, A. S.; Garron, T.; Tao, X.; Peng, B. H.; Wakamiya, M.; Chan, T. S.; Couch, R. B.; Tseng, C. T., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. *J Virol* **2015**, *89* (7), 3659–70. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403411/pdf/zjv3659.pdf>
8. (U) Amanat, F.; Krammer, F., SARS-CoV-2 vaccines: status report. *Journal of Immunology* **2020**, *Early View*. <https://marlin-prod.literatumonline.com/pb-assets/journals/research/immunity/SARS-CoV-2%20vaccines%20status%20report.pdf>
9. (U) Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0820-9>
10. (U) Anderson, K., Estimates of the clock and TMRCA for 2019-nCoV based on 27 genomes. <http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347> (accessed 01/26/2020).
11. (U) Angelopoulos, A. N.; Pathak, R.; Varma, R.; Jordan, M. I., Identifying and Correcting Bias from Time- and Severity-Dependent Reporting Rates in the Estimation of the COVID-19 Case Fatality Rate. *arXiv* **2020**. <https://arxiv.org/abs/2003.08592>
12. (U) Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F. X.; Chong, M.; Lee, M., Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4326>
13. (U) Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.-Y.; Chen, L.; Wang, M., Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*.
14. (U) Bao, L.; Deng, W.; Gao, H.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Liu, J.; Yu, P.; Xu, Y.; Qi, F.; Qu, Y.; Li, F.; Xiang, Z.; Yu, H.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Zhao, W.; Han, Y.; Zhao, L.; Liu, X.; Wei, Q.; Qin, C., Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. *bioRxiv* **2020**, 2020.03.13.990226. <https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.13.990226.full.pdf>

15. (U) Bao, L.; Deng, W.; Huang, B.; Gao, H.; Ren, L.; Wei, Q.; Yu, P.; Xu, Y.; Liu, J.; Qi, F.; Qu, Y.; Wang, W.; Li, F.; Lv, Q.; Xue, J.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Zhao, L.; Liu, P.; Zhao, L.; Ye, F.; Wang, H.; Zhou, W.; Zhu, N.; Zhen, W.; Yu, H.; Zhang, X.; Song, Z.; Guo, L.; Chen, L.; Wang, C.; Wang, Y.; Wang, X.; Xiao, Y.; Sun, Q.; Liu, H.; Zhu, F.; Ma, C.; Yan, L.; Yang, M.; Han, J.; Xu, W.; Tan, W.; Peng, X.; Jin, Q.; Wu, G.; Qin, C., The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice. *bioRxiv* **2020**, 2020.02.07.939389. <https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.07.939389.full.pdf>
16. (U) Barnard, D. L.; Hubbard, V. D.; Burton, J.; Smee, D. F.; Morrey, J. D.; Otto, M. J.; Sidwell, R. W., Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. *Antivir Chem Chemother* **2004**, *15* (1), 15-22. <https://journals.sagepub.com/doi/pdf/10.1177/095632020401500102>
17. (U) BBC, Coronavirus: California declares emergency after death. *BBC* 2020.
18. (U) Bedford, T., Cryptic Transmission of novel coronavirus revealed by genomic epidemiology. <https://bedford.io/blog/ncov-cryptic-transmission/>.
19. (U) Bedford, T.; Neher, R., Genomic epidemiology of novel coronavirus (nCoV) using data from GISAID. <https://nextstrain.org/ncov>.
20. (U) Belhadi, D.; Peiffer-Smadja, N.; Yazdanpanah, Y.; Mentré, F.; Laouénan, C., A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. *medRxiv* **2020**, 2020.03.18.20038190. <https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.18.20038190.full.pdf>
21. (U) BGI, BGI Responds to Novel Coronavirus with Real-Time Detection Kits, Deploys Emergency Team to Wuhan. 2020. <https://www.bgi.com/global/company/news/bgi-responds-to-novel-coronavirus-with-real-time-detection-kits-deploys-emergency-team-to-wuhan/>
22. (U) Biotech, M., Mesa Biotech Receives Emergency Use Authorization from FDA for a 30 Minute Point of Care Molecular COVID-19 Test. Mesa Biotech: 2020. <https://www.mesabiotech.com/news/euacoronavirus>
23. (U) Branswell, H., Sanofi announces it will work with HHS to develop a coronavirus vaccine. *Statnews*, Ed. 2020. <https://www.statnews.com/2020/02/18/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/>
24. (U) Brosseau, L. M., COMMENTARY: COVID-19 transmission messages should hinge on science. <http://www.cidrap.umn.edu/news-perspective/2020/03/commentary-covid-19-transmission-messages-should-hinge-science>.
25. (U) Brosseau, L. M.; Jones, R., Commentary: Protecting health workers from airborne MERS-CoV - learning from SARS. <http://www.cidrap.umn.edu/news-perspective/2014/05/commentary-protecting-health-workers-airborne-mers-cov-learning-sars>.
26. (U) Bryner, J., First US infant death linked to COVID-19 reported in Illinois. *LiveScience* 2020.
27. (U) Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2001282>

28. (U) Cao, W.; Liu, X.; Bai, T.; Fan, H.; Hong, K.; Song, H.; Han, Y.; Lin, L.; Ruan, L.; Li, T., High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. *Open Forum Infectious Diseases* **2020**. <https://doi.org/10.1093/ofid/ofaa102>
29. (U) Casadevall, A.; Pirofski, L.-a., The convalescent sera option for containing COVID-19. *The Journal of Clinical Investigation* **2020**, *130* (4). <https://doi.org/10.1172/JCI138003>
30. (U) Casanova, L. M.; Jeon, S.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Effects of air temperature and relative humidity on coronavirus survival on surfaces. *Applied and environmental microbiology* **2010**, *76* (9), 2712-2717. <https://www.ncbi.nlm.nih.gov/pubmed/20228108>
31. (U) CDC, 2019 Novel Coronavirus RT-PCR Identification Protocols. <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html>.
32. (U) CDC, Confirmed 2019-nCoV Cases Globally. <https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html>.
33. (U) CDC, Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>.
34. (U) CDC, Interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. <https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html>.
35. (U) CDC, Situation summary. <https://www.cdc.gov/coronavirus/2019-nCoV/summary.html>.
36. (U) CDC, Symptoms. <https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html>.
37. (U) CDC, C., China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html (accessed 01/27/2020).
38. (U) CenterWatch, SAB Biotherapeutics wins BARDA MERS treatment contract. <https://www.centerwatch.com/articles/14742>.
39. (U) Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* **2020**. <https://www.sciencedirect.com/science/article/pii/S0140673620301549>
40. (U) Chan, K. H.; Peiris, J. S.; Lam, S. Y.; Poon, L. L.; Yuen, K. Y.; Seto, W. H., The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. *Adv Virol* **2011**, *2011*, 734690. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265313/pdf/AV2011-734690.pdf>
41. (U) Chang, D.; Lin, M.; Wei, L.; Xie, L.; Zhu, G.; Dela Cruz, C. S.; Sharma, L., Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.1623>
https://jamanetwork.com/journals/jama/articlepdf/2761043/jama_chang_2020_Id_200007.pdf
42. (U) Changzheng, L. J. L., Experts in the medical treatment team: Wuhan's unexplained viral pneumonia patients can be controlled more. <https://www.cn-healthcare.com/article/20200110/content-528579.html>.
43. (U) Chen, C.; Cao, M.; Peng, L.; Guo, X.; Yang, F.; Wu, W.; Chen, L.; Yang, Y.; Liu, Y.; Wang, F., Coronavirus Disease-19 Among Children Outside Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546071
44. (U) Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; Chen, B.; Lu, M.; Luo, Y.; Zhang, J.; Yin, P.; Wang, X., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv* **2020**, 2020.03.17.20037432. <https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20037432.full.pdf>

45. (U) Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **2020**.
<https://www.ncbi.nlm.nih.gov/pubmed/32007143>
46. (U) Chin, A.; Chu, J.; Perera, M.; Hui, K.; Yen, H.-L.; Chan, M.; Peiris, M.; Poon, L., Stability of SARS-CoV-2 in different environmental conditions. *medRxiv* **2020**, 2020.03.15.20036673. <https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.15.20036673.full.pdf>
47. (U) Chughtai, A. A.; Seale, H.; MacIntyre, C. R., Use of cloth masks in the practice of infection control—evidence and policy gaps. *Int J Infect Control* **2013**, *9* (3), doi: 10.3396/IJIC.v9i3.020.13.
48. (U) Cockrell, A. S.; Yount, B. L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.-C.; Marasco, W. A.; Heise, M. T.; Baric, R. S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology* **2016**, *2* (2), 1-11.
49. (U) Cohen, J., Mining coronavirus genomes for clues to the outbreak's origins. *Science* **2020**.
50. (U) Cohen, J., Wuhan seafood market may not be source of novel virus spreading globally.
<https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally> (accessed 01/27/2020).
51. (U) Control, E. E. C. f. D. P. a., *Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2*; European Centre for Disease Prevention and Control: European Centre for Disease Prevention and Control, 2020.
<https://www.ecdc.europa.eu/en/publications-data/interim-guidance-environmental-cleaning-non-healthcare-facilities-exposed-2019#no-link>
52. (U) Corman, V. M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D. K.; Bleicker, T.; Brunink, S.; Schneider, J.; Schmidt, M. L.; Mulders, D. G.; Haagmans, B. L.; van der Veer, B.; van den Brink, S.; Wijsman, L.; Goderski, G.; Romette, J. L.; Ellis, J.; Zambon, M.; Peiris, M.; Goossens, H.; Reusken, C.; Koopmans, M. P.; Drosten, C., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* **2020**, *25* (3).
<https://www.ncbi.nlm.nih.gov/pubmed/31992387>
53. (U) Coughlin, M. M.; Prabhakar, B. S., Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. *Reviews in medical virology* **2012**, *22* (1), 2-17.
<https://www.ncbi.nlm.nih.gov/pubmed/21905149>
54. (U) Cowling, B. J.; Ali, S. T.; Ng, T. W. Y.; Tsang, T. K.; Li, J. C. M.; Fong, M. W.; Liao, Q.; Kwan, M. Y.; Lee, S. L.; Chiu, S. S.; Wu, J. T.; Wu, P.; Leung, G. M., Impact assessment of non-pharmaceutical interventions against COVID-19 and influenza in Hong Kong: an observational study. *medRxiv* **2020**, 2020.03.12.20034660. <https://www.medrxiv.org/content/medrxiv/early/2020/03/16/2020.03.12.20034660.full.pdf>
55. (U) Daily, H., Wuhan Institute of Virology, Chinese Academy of Sciences and others have found that 3 drugs have a good inhibitory effect on new coronavirus. Chen, L., Ed. 2020. http://news.cnhubei.com/content/2020-01/28/content_12656365.html
56. (U) Dato, V. M.; Hostler, D.; Hahn, M. E., Simple respiratory mask. *Emerg Infect Dis* **2006**, *12* (6), 1033-4.
<https://www.ncbi.nlm.nih.gov/pubmed/16752475>
57. (U) De Albuquerque, N.; Baig, E.; Ma, X.; Zhang, J.; He, W.; Rowe, A.; Habal, M.; Liu, M.; Shalev, I.; Downey, G. P.; Gorczynski, R.; Butany, J.; Leibowitz, J.; Weiss, S. R.; McGilvray, I. D.; Phillips, M. J.; Fish, E. N.; Levy, G. A., Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. *J Virol* **2006**, *80* (21), 10382-94.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1641767/pdf/0747-06.pdf>

58. (U) Dediego, M. L.; Pewe, L.; Alvarez, E.; Rejas, M. T.; Perlman, S.; Enjuanes, L., Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008**, 376 (2), 379-389. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810402/>
59. (U) Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route. *bioRxiv* **2020**, 2020.03.13.990036. <https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.13.990036.full.pdf>
60. (U) Dong, N.; Yang, X.; Ye, L.; Chen, K.; Chan, E. W.-C.; Yang, M.; Chen, S., Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. *bioRxiv* **2020**, 2020.01.20.913368. <https://www.biorxiv.org/content/biorxiv/early/2020/01/22/2020.01.20.913368.full.pdf>
61. (U) Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S., Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* **2020**, e20200702. <https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf>
62. (U) Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., The serial interval of COVID-19 from publicly reported confirmed cases. *medRxiv* **2020**, 2020.02.19.20025452. <https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.02.19.20025452.full.pdf>
63. (U) Duan, S.; Zhao, X.; Wen, R.; Huang, J.-j.; Pi, G.; Zhang, S.; Han, J.; Bi, S.; Ruan, L.; Dong, X.-p., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomedical and environmental sciences: BES* **2003**, 16 (3), 246-255.
64. (U) Duan, S. M.; Zhao, X. S.; Wen, R. F.; Huang, J. J.; Pi, G. H.; Zhang, S. X.; Han, J.; Bi, S. L.; Ruan, L.; Dong, X. P., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomed Environ Sci* **2003**, 16 (3), 246-55.
65. (U) FDA, *Emergency Use Authorization*; Food and Drug Administration: 2020. <https://www.fda.gov/media/136529/download>
66. (U) FDA, *ID NOW COVID-19*; Food and Drug Administration: 2020. <https://www.fda.gov/media/136525/download>
67. (U) FDA, *Investigational COVID-19 Convalescent Plasma - Emergency INDs*; Food and Drug Administration: 2020. <https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-ind>
68. (U) FDA, *Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency; Immediately in Effect Guidance for Industry and Food and Drug Administration Staff*. 2020. <https://www.regulations.gov/docket?D=FDA-2020-D-0987>
69. (U) Ferguson, N.; Laydon, D.; Nedjati-Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Dorigatti, I.; Fu, H.; Gaythorpe, K.; Green, W.; Hamlet, A.; Hinsley, W.; Okell, L.; van Elsland, S.; Thompson, H.; Verity, R.; Volz, E.; Wang, H.; Wang, Y.; Walker, P.; Walters, C.; Winskill, P.; Whittaker, C.; Donnelly, C.; Riley, S.; Ghani, A., *Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*; 2020. <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf>
70. (U) Gautret, P.; Lagier, J.-C.; Parola, P.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V. E.; Dupont, H. T., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* **2020**, 105949.

71. (U) Guan, L.; Zhou, L.; Zhang, J.; Peng, W.; Chen, R., More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. *European Respiratory Journal* **2020**, *55* (3), 2000352. <https://erj.ersjournals.com/content/erj/55/3/2000352.full.pdf>
72. (U) Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S.; Du, B.; Li, L.-j.; Zeng, G.; Yuen, K.-Y.; Chen, R.-c.; Tang, C.-l.; Wang, T.; Chen, P.-y.; Xiang, J.; Li, S.-y.; Wang, J.-l.; Liang, Z.-j.; Peng, Y.-x.; Wei, L.; Liu, Y.; Hu, Y.-h.; Peng, P.; Wang, J.-m.; Liu, J.-y.; Chen, Z.; Li, G.; Zheng, Z.-j.; Qiu, S.-q.; Luo, J.; Ye, C.-j.; Zhu, S.-y.; Zhong, N.-s., Clinical characteristics of 2019 novel coronavirus infection in China. *medRxiv* **2020**, 2020.02.06.20020974. <https://www.medrxiv.org/content/medrxiv/early/2020/02/09/2020.02.06.20020974.full.pdf>
73. (U) HHS, 2019-nCoV Update. 2020. https://www.hhs.gov/live/live-2/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmedia%2Fpress%2F2020%2Fa0128-hhs-coronavirus-update.html#11465
74. (U) Hill, V.; Rambaut, A., Phylodynamic analysis of SARS-CoV-2 | Update 2020-03-06. *Virological*: 2020. <http://virological.org/t/phylodynamic-analysis-of-sars-cov-2-update-2020-03-06/420>
75. (U) Hoehl, S.; Berger, A.; Kortenbusch, M.; Cinatl, J.; Bojkova, D.; Rabenau, H.; Behrens, P.; Böddinghaus, B.; Götsch, U.; Naujoks, F.; Neumann, P.; Schork, J.; Tiarks-Jungk, P.; Walczok, A.; Eickmann, M.; Vehreschild, M. J. G. T.; Kann, G.; Wolf, T.; Gottschalk, R.; Ciesek, S., Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001899>
76. (U) Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30183-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)
77. (U) Hulkower, R. L.; Casanova, L. M.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. *American journal of infection control* **2011**, *39* (5), 401-407. <https://www.sciencedirect.com/science/article/pii/S0196655310009004>
78. (U) IDEXX, Leading Veterinary Diagnostic Company Sees No COVID-19 Cases in Pets. IDEXX: 2020. <https://www.idexx.com/en/about-idexx/news/no-covid-19-cases-pets/>
79. (U) Imai, N.; Dorigatti, I.; Cori, A.; Riley, S.; Ferguson, N., Estimating the potential total number of novel Coronavirus cases in Wuhan City, China. <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/2019-nCoV-outbreak-report-17-01-2020.pdf>
80. (U) JHU, Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE. <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>.
81. (U) Jing, C.; Wenjie, S.; Jianping, H.; Michelle, G.; Jing, W.; Guiqing, H., Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. *Emerging Infectious Disease journal* **2020**, *26* (6). https://wwwnc.cdc.gov/eid/article/26/6/20-0412_article
82. (U) Johnson, J. a., Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. Johnson and Johnson: 2020. <https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use>

83. (U) Joseph, A., CDC developing serologic tests that could reveal full scope of U.S. coronavirus outbreak. *STAT* 2020.
84. (U) Kraemer, M. U. G.; Yang, C.-H.; Gutierrez, B.; Wu, C.-H.; Klein, B.; Pigott, D. M.; du Plessis, L.; Faria, N. R.; Li, R.; Hanage, W. P.; Brownstein, J. S.; Layan, M.; Vespignani, A.; Tian, H.; Dye, C.; Pybus, O. G.; Scarpino, S. V., The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* **2020**, eabb4218. <https://science.sciencemag.org/content/sci/early/2020/03/25/science.abb4218.full.pdf>
85. (U) Kratzel, A.; Todt, D.; V'kovski, P.; Steiner, S.; Gultom, M. L.; Thao, T. T. N.; Ebert, N.; Holwerda, M.; Steinmann, J.; Niemeyer, D.; Dijkman, R.; Kampf, G.; Drosten, C.; Steinmann, E.; Thiel, V.; Pfaender, S., Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. *bioRxiv* **2020**, 2020.03.10.986711. <https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.10.986711.full.pdf>
86. (U) Kupferschmidt, K.; Cohen, J., WHO launches global megatrial of the four most promising coronavirus treatments. *Science* 2020.
87. (U) Lai, M. Y.; Cheng, P. K.; Lim, W. W., Survival of severe acute respiratory syndrome coronavirus. *Clinical Infectious Diseases* **2005**, 41 (7), e67-e71. <https://academic.oup.com/cid/article/41/7/e67/310340>
88. (U) Lam, T. T.-Y.; Shum, M. H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W. Y.-M.; Li, W.-J.; Li, L.-F.; Leung, G. M.; Holmes, E. C.; Hu, Y.-L.; Guan, Y., Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2169-0>
89. (U) Lan, L.; Xu, D.; Ye, G.; Xia, C.; Wang, S.; Li, Y.; Xu, H., Positive RT-PCR Test Results in Patients Recovered From COVID-19. *Jama* **2020**. <https://jamanetwork.com/journals/jama/fullarticle/2762452>
90. (U) Lau, S., Coronavirus: WHO official says there's no evidence of 'reinfected' patients in China <https://www.scmp.com/news/china/society/article/3074045/coronavirus-who-official-says-theres-no-evidence-reinfected>.
91. (U) Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine* **2020**. <https://doi.org/10.7326/M20-0504>
92. (U) Levine, J., Scientists race to develop vaccine to deadly China coronavirus. <https://nypost.com/2020/01/25/scientists-race-to-develop-vaccine-to-deadly-china-coronavirus/>.
93. (U) Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A. K.; Reznikov, L. R.; Gibson-Corley, K. N.; Meyerholz, D. K.; McCray, P. B., Jr., Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis* **2016**, 213 (5), 712-22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747621/pdf/jiv499.pdf>
94. (U) Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K. S. M.; Lau, E. H. Y.; Wong, J. Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T. T. Y.; Wu, J. T.; Gao, G. F.; Cowling, B. J.; Yang, B.; Leung, G. M.; Feng, Z., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2001316> <https://www.nejm.org/doi/10.1056/NEJMoa2001316>
95. (U) Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* **2020**, eabb3221. <https://science.sciencemag.org/content/sci/early/2020/03/13/science.abb3221.full.pdf>

96. (U) Li, X.; Zai, J.; Zhao, Q.; Nie, Q.; Li, Y.; Foley, B. T.; Chaillon, A., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of Medical Virology* **2020**, n/a (n/a). <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25731>
97. (U) Ling, Y.; Xu, S. B.; Lin, Y. X.; Tian, D.; Zhu, Z. Q.; Dai, F. H.; Wu, F.; Song, Z. G.; Huang, W.; Chen, J.; Hu, B. J.; Wang, S.; Mao, E. Q.; Zhu, L.; Zhang, W. H.; Lu, H. Z., Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl)* **2020**.
98. (U) Liu, H.; Wang, L.-L.; Zhao, S.-J.; Kwak-Kim, J.; Mor, G.; Liao, A.-H., Why are pregnant women susceptible to viral infection: an immunological viewpoint? *Journal of Reproductive Immunology* **2020**, 103122.
<http://www.sciencedirect.com/science/article/pii/S0165037820300437>
99. (U) Liu, P.; Chen, W.; Chen, J.-P., Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (*Manis javanica*). *Viruses* **2019**, 11 (11), 979. <https://www.mdpi.com/1999-4915/11/11/979>
100. (U) Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? *bioRxiv* **2020**, 2020.02.18.954628. <http://biorxiv.org/content/early/2020/02/20/2020.02.18.954628.abstract>
101. (U) Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L.; Wu, P.; Zhang, B.; Lu, Y.; Xia, L.; Huang, L.; Yang, Y.; Liu, F.; Semple, M. G.; Cowling, B. J.; Lan, K.; Sun, Z.; Yu, H.; Liu, Y., Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2003717>
102. (U) Liu, Y.; Funk, S.; Flasche, S., *The Contribution of Pre-symptomatic Transmission to the COVID-19 Outbreak*; London School of Hygiene and Tropical Medicine: 2020. <https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html>
103. (U) Liu, Y.; Ning, Z.; Chen, Y.; Guo, M.; Liu, Y.; Gali, N. K.; Sun, L.; Duan, Y.; Cai, J.; Westerdahl, D.; Liu, X.; Ho, K.-f.; Kan, H.; Fu, Q.; Lan, K., Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak. *bioRxiv* **2020**, 2020.03.08.982637. <https://www.biorxiv.org/content/biorxiv/early/2020/03/10/2020.03.08.982637.full.pdf>
104. (U) Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu, W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan, W., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
105. (U) Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y. Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; Wu, C.; Liu, H.; Liu, D.; Shao, J.; Peng, X.; Yang, Y.; Liu, Z.; Xiang, Y.; Zhang, F.; Silva, R. M.; Pinkerton, K. E.; Shen, K.; Xiao, H.; Xu, S.; Wong, G. W. K., SARS-CoV-2 Infection in Children. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2005073>
106. (U) Luo, L.; Liu, D.; Liao, X.-l.; Wu, X.-b.; Jing, Q.-l.; Zheng, J.-z.; Liu, F.-h.; Yang, S.-g.; Bi, B.; Li, Z.-h.; Liu, J.-p.; Song, W.-q.; Zhu, W.; Wang, Z.-h.; Zhang, X.-r.; Chen, P.-l.; Liu, H.-m.; Cheng, X.; Cai, M.-c.; Huang, Q.-m.; Yang, P.; Yang, X.-f.; Huang, Z.-g.; Tang, J.-l.; Ma, Y.; Mao, C., Modes of contact and risk of transmission in COVID-19 among close contacts. *medRxiv* **2020**, 2020.03.24.20042606.
<https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.24.20042606.full.pdf>
107. (U) Luo, W.; Majumder, M. S.; Liu, D.; Poirier, C.; Mandl, K. D.; Lipsitch, M.; Santillana, M., The role of absolute humidity on transmission rates of the COVID-19 outbreak. *medRxiv* **2020**, 2020.02.12.20022467.
<https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.12.20022467.full.pdf>

108. (U) Majumder, M.; Mandl, K., Early transmissibility assessment of a novel coronavirus in Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524675
109. (U) Matthay, M. A.; Aldrich, J. M.; Gotts, J. E., Treatment for severe acute respiratory distress syndrome from COVID-19. *The Lancet Respiratory Medicine* **2020**. [https://doi.org/10.1016/S2213-2600\(20\)30127-2](https://doi.org/10.1016/S2213-2600(20)30127-2)
110. (U) Maxmen, A., How blood from coronavirus survivors might save lives. *Nature News* **2020**.
111. (U) Moriarty, L. F.; Plucinski, M. M.; Marston, B. J. e. a., Public Health Responses fo COVID-19 Outbreaks on Cruise Ships - Worldwide, February - March 2020. *MMWR* **2020**, (ePub: 23 March 2020). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e3.htm>
112. (U) Munster, V. J.; Feldmann, F.; Williamson, B. N.; van Doremalen, N.; Pérez-Pérez, L.; Schulz, J.; Meade-White, K.; Okumura, A.; Callison, J.; Brumbaugh, B.; Avanzato, V. A.; Rosenke, R.; Hanley, P. W.; Saturday, G.; Scott, D.; Fischer, E. R.; de Wit, E., Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* **2020**, 2020.03.21.001628. <https://www.biorxiv.org/content/biorxiv/early/2020/03/21/2020.03.21.001628.full.pdf>
113. (U) NIH, NIH clinical trial of remdesivir to treat COVID-19 begins <https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins>.
114. (U) Onder, G.; Rezza, G.; Brusaferro, S., Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4683>
115. (U) Ong, S. W. X.; Tan, Y. K.; Chia, P. Y.; Lee, T. H.; Ng, O. T.; Wong, M. S. Y.; Marimuthu, K., Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama* **2020**. https://jamanetwork.com/journals/jama/articlepdf/2762692/jama_ong_2020_id_200016.pdf
116. (U) Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R. L.; Yang, L.; Zheng, C., Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology* *0* (0), 200370. <https://pubs.rsna.org/doi/abs/10.1148/radiol.2020200370>
117. (U) Pan, L.; Mu, M.; Yang, P.; Sun, Y.; Wang, R.; Yan, J.; Li, P.; Hu, B.; Wang, J.; Hu, C.; Jin, Y.; Niu, X.; Ping, R.; Du, Y.; Li, T.; Xu, G.; Hu, Q.; Tu, L., Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *The American Journal of Gastroenterology* **2020**. https://journals.lww.com/ajg/Documents/COVID_Digestive_Symptoms_AJG_Preproof.pdf
118. (U) Park, S. W.; Champredon, D.; Earn, D. J. D.; Li, M.; Weitz, J. S.; Grenfell, B. T.; Dushoff, J., Reconciling early-outbreak preliminary estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus (2019-nCoV) outbreak. **2020**, 1-13.
119. (U) Prem, K.; Liu, Y.; Russell, T. W.; Kucharski, A. J.; Eggo, R. M.; Davies, N.; Flasche, S.; Clifford, S.; Pearson, C. A. B.; Munday, J. D.; Abbott, S.; Gibbs, H.; Rosello, A.; Quilty, B. J.; Jombart, T.; Sun, F.; Diamond, C.; Gimma, A.; van Zandvoort, K.; Funk, S.; Jarvis, C. I.; Edmunds, W. J.; Bosse, N. I.; Hellewell, J.; Jit, M.; Klepac, P., The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. *The Lancet Public Health* **2020**. [https://doi.org/10.1016/S2468-2667\(20\)30073-6](https://doi.org/10.1016/S2468-2667(20)30073-6)
120. (U) Pyankov, O. V.; Bodnev, S. A.; Pyankova, O. G.; Agranovski, I. E., Survival of aerosolized coronavirus in the ambient air. *Journal of Aerosol Science* **2018**, *115*, 158-163. <http://www.sciencedirect.com/science/article/pii/S0021850217302239>

121. (U) Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30198-5](https://doi.org/10.1016/S1473-3099(20)30198-5)
122. (U) Rabenau, H.; Kampf, G.; Cinatl, J.; Doerr, H., Efficacy of various disinfectants against SARS coronavirus. *Journal of Hospital Infection* **2005**, *61* (2), 107-111. <https://www.sciencedirect.com/science/article/pii/S0195670105000447>
123. (U) Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W., Stability and inactivation of SARS coronavirus. *Med Microbiol Immunol* **2005**, *194* (1-2), 1-6. <https://link.springer.com/content/pdf/10.1007/s00430-004-0219-0.pdf>
124. (U) Rambaut, A., Phylodynamic analysis of nCoV-2019 genomes - 27-Jan-2020. <http://virological.org/t/phylogenetic-analysis-of-ncov-2019-genomes-27-jan-2020/353>.
125. (U) Remuzzi, A.; Remuzzi, G., COVID-19 and Italy: what next? *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30627-9](https://doi.org/10.1016/S0140-6736(20)30627-9)
126. (U) Ren, X.; Liu, Y.; Chen, H.; Liu, W.; Guo, Z.; Chen, C.; Zhou, J.; Xiao, Q.; Jiang, G.-M.; Shan, H., Application and Optimization of RT-PCR in Diagnosis of SARS-CoV-2 Infection. *medRxiv* **2020**.
127. (U) Rengasamy, S.; Eimer, B.; Shaffer, R. E., Simple respiratory protection--evaluation of the filtration performance of cloth masks and common fabric materials against 20-1000 nm size particles. *Ann Occup Hyg* **2010**, *54* (7), 789-98. <https://www.ncbi.nlm.nih.gov/pubmed/20584862>
128. (U) Richter, W.; Hofacre, K.; Willenberg, Z., *Final Report for the Bioquell Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators*; Battelle Memorial Institute: 2016. <http://wayback.archive-it.org/7993/20170113034232/http://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMRegulatoryScience/UCM516998.pdf>
129. (U) Riou, J.; Althaus, C. L., Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* **2020**, *25* (4), 2000058. <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.2000058>
130. (U) Roberts, M., Coronavirus: US volunteers test first vaccine. *BBC* 2020.
131. (U) Robertson, D., nCoV's relationship to bat coronaviruses & recombination signals (no snakes) **2020**. <http://virological.org/t/ncovs-relationship-to-bat-coronaviruses-recombination-signals-no-snakes/331>
132. (U) Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M.; de Meulder, D.; van Amerongen, G.; van de Brand, J.; Okba, N.; Schipper, D.; van Run, P.; Leijten, L.; Verschoor, E.; Verstrepen, B.; Langermans, J.; Drosten, C.; Fentener van Vlissingen, M.; Fouchier, R.; de Swart, R. L.; Koopmans, M.; Haagmans, B., Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model. *bioRxiv* **2020**, 2020.03.17.995639. <https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.17.995639.full.pdf>
133. (U) Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirgmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001468>
<https://www.nejm.org/doi/10.1056/NEJMc2001468>
134. (U) Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine* **2020**. <https://doi.org/10.1007/s00134-020-05991-x>

135. (U) Saknimit, M.; Inatsuki, I.; Sugiyama, Y.; Yagami, K., Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals. *Jikken Dobutsu* **1988**, *37* (3), 341-5. https://www.jstage.jst.go.jp/article/expanim1978/37/3/37_3_341/_pdf
136. (U) Schnirring, L., New coronavirus infects health workers, spreads to Korea. <http://www.cidrap.umn.edu/news-perspective/2020/01/new-coronavirus-infects-health-workers-spreads-korea>.
137. (U) Security, J. C. f. H., 2019-nCoV resources and updates on the emerging novel coronavirus. **2020**. <http://www.centerforhealthsecurity.org/resources/2019-nCoV/>
138. (U) Sheahan, T. P.; Sims, A. C.; Graham, R. L.; Menachery, V. D.; Gralinski, L. E.; Case, J. B.; Leist, S. R.; Pyrc, K.; Feng, J. Y.; Trantcheva, I.; Bannister, R.; Park, Y.; Babusis, D.; Clarke, M. O.; Mackman, R. L.; Spahn, J. E.; Palmiotti, C. A.; Siegel, D.; Ray, A. S.; Cihlar, T.; Jordan, R.; Denison, M. R.; Baric, R. S., Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* **2017**, *9* (396). <https://stm.sciencemag.org/content/scitransmed/9/396/eaal3653.full.pdf>
139. (U) Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; Wei, J.; Xiao, H.; Yang, Y.; Qu, J.; Qing, L.; Chen, L.; Xu, Z.; Peng, L.; Li, Y.; Zheng, H.; Chen, F.; Huang, K.; Jiang, Y.; Liu, D.; Zhang, Z.; Liu, Y.; Liu, L., Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4783>
140. (U) Sheridan, C., Coronavirus and the race to distribute reliable diagnostics. <https://www.nature.com/articles/d41587-020-00002-2>.
141. (U) Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.0950>
142. (U) Shi, W.; Peng, X.; Liu, T.; Cheng, Z.; Lu, H.; Yang, S.; Zhang, J.; Li, F.; Wang, M.; Zhang, X.; Gao, Y.; Shi, Y.; Zhang, Z.; Shan, F., Deep Learning-Based Quantitative Computed Tomography Model in Predicting the Severity of COVID-19: A Retrospective Study in 196 Patients. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546089
143. (U) Su, Y. C.; Anderson, D. E.; Young, B. E.; Zhu, F.; Linster, M.; Kalimuddin, S.; Low, J. G.; Yan, Z.; Jayakumar, J.; Sun, L.; Yan, G. Z.; Mendenhall, I. H.; Leo, Y.-S.; Lye, D. C.; Wang, L.-F.; Smith, G. J., Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2. *bioRxiv* **2020**, 2020.03.11.987222. <https://www.biorxiv.org/content/biorxiv/early/2020/03/12/2020.03.11.987222.full.pdf>
144. (U) ter Meulen, J.; van den Brink, E. N.; Poon, L. L.; Marissen, W. E.; Leung, C. S.; Cox, F.; Cheung, C. Y.; Bakker, A. Q.; Bogaards, J. A.; van Deventer, E.; Preiser, W.; Doerr, H. W.; Chow, V. T.; de Kruif, J.; Peiris, J. S.; Goudsmit, J., Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Med* **2006**, *3* (7), e237. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1483912/pdf/pmed.0030237.pdf>
145. (U) The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly* **2020**, *2*, 1-10. <http://weekly.chinacdc.cn/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51>
146. (U) Thevarajan, I.; Nguyen, T. H. O.; Koutsakos, M.; Druce, J.; Caly, L.; van de Sandt, C. E.; Jia, X.; Nicholson, S.; Catton, M.; Cowie, B.; Tong, S. Y. C.; Lewin, S. R.; Kedzierska, K., Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0819-2>

147. (U) Thomas, P. R.; Karriker, L. A.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Crawford, K. K.; Bates, J. L.; Hammen, K. J.; Holtkamp, D. J., Evaluation of time and temperature sufficient to inactivate porcine epidemic diarrhea virus in swine feces on metal surfaces. *Journal of Swine Health and Production* **2015**, *23* (2), 84.
148. (U) Thomas, P. R.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Myers, J. N., Methods for inactivating PEDV in Hog Trailers. *Animal Industry Report* **2015**, *661* (1), 91.
149. (U) To, K. K.-W.; Tsang, O. T.-Y.; Yip, C. C.-Y.; Chan, K.-H.; Wu, T.-C.; Chan, J. M.-C.; Leung, W.-S.; Chik, T. S.-H.; Choi, C. Y.-C.; Kandamby, D. H.; Lung, D. C.; Tam, A. R.; Poon, R. W.-S.; Fung, A. Y.-F.; Hung, I. F.-N.; Cheng, V. C.-C.; Chan, J. F.-W.; Yuen, K.-Y., Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clinical Infectious Diseases* **2020**. <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa149/5734265>
150. (U) van Doremalen, N.; Bushmaker, T.; Morris, D.; Holbrook, M.; Gamble, A.; Williamson, B.; Tamin, A.; Harcourt, J.; Thornburg, N.; Gerber, S.; Lloyd-Smith, J.; de Wit, E.; Munster, V., Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. *medRxiv* **2020**, 2020.03.09.20033217. <https://www.medrxiv.org/content/medrxiv/early/2020/03/10/2020.03.09.20033217.full.pdf>
151. (U) van Doremalen, N.; Bushmaker, T.; Munster, V. J., Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. *Euro Surveill* **2013**, *18* (38).
152. (U) Verdict, Cepheid to develop automated molecular test for coronavirus. Verdict Medical Devices: 2020. <https://www.medicaldevice-network.com/news/cepheid-automated-test-coronavirus/>
153. (U) Wan, Y.; Shang, J.; Graham, R.; Baric, R. S.; Li, F., Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *Journal of Virology* **2020**, JVI.00127-20. <https://jvi.asm.org/content/jvi/early/2020/01/23/JVI.00127-20.full.pdf>
154. (U) Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.1585> https://jamanetwork.com/journals/jama/articlepdf/2761044/jama_wang_2020_oi_200019.pdf
155. (U) Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W., Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.3786>
156. (U) Weston, S.; Haupt, R.; Logue, J.; Matthews, K.; Frieman, M. B., FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 *in vitro*. *bioRxiv* **2020**, 2020.03.25.008482. <https://www.biorxiv.org/content/biorxiv/early/2020/03/27/2020.03.25.008482.full.pdf>
157. (U) WHO, Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR -Protocol and preliminary evaluation as of Jan 13, 2020. https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2 (accessed 01/26/2020).
158. (U) WHO, *Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected*; 2020. [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)
159. (U) WHO, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.

160. (U) WHO, *Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations*; World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations>
161. (U) WHO, Novel Coronavirus (2019-nCoV) Situation Report-5 25 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d_4.
162. (U) WHO, Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 2019-nCoV in humans. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>.
163. (U) Woelfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Mueller, M. A.; Niemeyer, D.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Bruenink, S.; Schneider, J.; Ehmann, R.; Zwirgmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized cases of coronavirus disease 2019. **2020**.
164. (U) Wolff, M. H.; Sattar, S. A.; Adegbunrin, O.; Tetro, J., Environmental survival and microbicide inactivation of coronaviruses. In *Coronaviruses with special emphasis on first insights concerning SARS*, Springer: 2005; pp 201-212.
165. (U) Wong, M. C.; Javornik Cregeen, S. J.; Ajami, N. J.; Petrosino, J. F., Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *bioRxiv* **2020**, 2020.02.07.939207. <https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.07.939207.full.pdf>
166. (U) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* **2020**, 2020.02.11.944462. <https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf>
167. (U) Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30260-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext)
168. (U) Xinhua, China detects large quantity of novel coronavirus at Wuhan seafood market http://www.xinhuanet.com/english/2020-01/27/c_138735677.htm.
169. (U) Xu, X.; Han, M.; Li, T.; Sun, W.; Wang, D.; Fu, B.; Zhou, Y.; Zheng, X.; Yang, Y.; Li, X.; Zhang, X.; Pan, A.; Wei, H., Effective Treatment of Severe COVID-19 Patients with Tocilizumab. *ChinaXiv* **2020**. <http://chinaxiv.org/abs/202003.00026>
170. (U) Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; Tai, Y.; Bai, C.; Gao, T.; Song, J.; Xia, P.; Dong, J.; Zhao, J.; Wang, F.-S., Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30260-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext)
171. (U) Yoon, I.-K.; Kim, J. H., First clinical trial of a MERS coronavirus DNA vaccine. *The Lancet Infectious Diseases* **2019**, *19* (9), 924-925. [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(19\)30397-4/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30397-4/fulltext)
172. (U) Yu, W.-B.; Tang, G.-D.; Zhang, L.; Corlett, R. T., Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. *ChinaXiv* **2020**. <http://www.chinaxiv.org/abs/202002.00033>
173. (U) Zhao; Musa; Lin; Ran; Yang; Wang; Lou; Yang; Gao; He; Wang, Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *Journal of Clinical Medicine* **2020**, *9* (2), 388.

174. (U) Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; Tan, W.; Jiang, S.; Sun, S.; Zhou, Y., Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS One* **2015**, *10* (12), e0145561. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689477/pdf/pone.0145561.pdf>
175. (U) Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; Qian, S.; Hong, C.; Wang, F.; Liu, Y.; Wang, Z.; He, Q.; He, B.; Zhang, T.; Ge, S.; Liu, L.; Zhang, J.; Xia, N.; Zhang, Z., Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546052#
176. (U) Zhen-Dong, T.; An, T.; Ke-Feng, L.; Peng, L.; Hong-Ling, W.; Jing-Ping, Y.; Yong-Li, Z.; Jian-Bo, Y., Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging Infectious Disease journal* **2020**, *26* (5). https://wwwnc.cdc.gov/eid/article/26/5/20-0198_article
177. (U) Zhongchu, L., The sixth press conference of "Prevention and Control of New Coronavirus Infected Pneumonia". Hubei Provincial Government: 2020. http://www.hubei.gov.cn/hbfb/xwfbh/202001/t20200128_2015591.shtml
178. (U) Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
179. (U) Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.; Shi, Z.-L., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* **2020**, 2020.01.22.914952. <https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf>
180. (U) Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J., SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001737>